File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.oraloncology.2005.01.008
- Scopus: eid_2-s2.0-20444490061
- PMID: 15975521
- WOS: WOS:000230570600005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma
Title | A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma |
---|---|
Authors | |
Keywords | Chemotherapy Cisplatin Docetaxel Nasopharyngeal carcinoma |
Issue Date | 2005 |
Publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/oraloncology |
Citation | Oral Oncology, 2005, v. 41 n. 6, p. 589-595 How to Cite? |
Abstract | To evaluate the efficacy and safety of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma (NPC). Nineteen previously untreated metastatic NPC patients received one to six cycles of docetaxel and cisplatin. Fifteen patients received at least three cycles. The starting dose was 75 mg/m2 every three weeks for both drugs in 15 patients, and 60 mg/m2 for both drugs in four patients. All patients were included in toxicity and survival analysis, and 16 patients were evaluable for response. Median follow-up time was 11.6 months. Hematological toxicity was severe with Grade 4 neutropenia in 78.9% patients and 51.3% cycles. Febrile neutropenia occurred in 42% patients and 12.5% cycles, with two septic deaths in the population treated with 75 mg/m2. Patients treated with a dose subsequently reduced to 60 mg/m2 had a lower incidence of Grade 4 neutropenia and no incidence of neutropenic fever/sepsis. Overall response rate was 62.5%, with a 95% confidence interval of 35-85%. Partial and complete response rates were 56.3% and 6.3%, respectively. Median time to progression was 5.6 months and median survival was 12.4 months. Three patients (15.6%) survived >2 years following chemotherapy. The combination of docetaxel and cisplatin is active in metastatic NPC. The dose of 60 mg/m2 for both drugs without colony-stimulating factor support should be further evaluated as a high incidence of febrile neutropenia was observed with 75 mg/m2 dose. |
Persistent Identifier | http://hdl.handle.net/10722/211342 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.257 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chua, DTT | - |
dc.contributor.author | Sham, JST | - |
dc.contributor.author | Au, GKH | - |
dc.date.accessioned | 2015-07-08T07:08:44Z | - |
dc.date.available | 2015-07-08T07:08:44Z | - |
dc.date.issued | 2005 | - |
dc.identifier.citation | Oral Oncology, 2005, v. 41 n. 6, p. 589-595 | - |
dc.identifier.issn | 1368-8375 | - |
dc.identifier.uri | http://hdl.handle.net/10722/211342 | - |
dc.description.abstract | To evaluate the efficacy and safety of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma (NPC). Nineteen previously untreated metastatic NPC patients received one to six cycles of docetaxel and cisplatin. Fifteen patients received at least three cycles. The starting dose was 75 mg/m2 every three weeks for both drugs in 15 patients, and 60 mg/m2 for both drugs in four patients. All patients were included in toxicity and survival analysis, and 16 patients were evaluable for response. Median follow-up time was 11.6 months. Hematological toxicity was severe with Grade 4 neutropenia in 78.9% patients and 51.3% cycles. Febrile neutropenia occurred in 42% patients and 12.5% cycles, with two septic deaths in the population treated with 75 mg/m2. Patients treated with a dose subsequently reduced to 60 mg/m2 had a lower incidence of Grade 4 neutropenia and no incidence of neutropenic fever/sepsis. Overall response rate was 62.5%, with a 95% confidence interval of 35-85%. Partial and complete response rates were 56.3% and 6.3%, respectively. Median time to progression was 5.6 months and median survival was 12.4 months. Three patients (15.6%) survived >2 years following chemotherapy. The combination of docetaxel and cisplatin is active in metastatic NPC. The dose of 60 mg/m2 for both drugs without colony-stimulating factor support should be further evaluated as a high incidence of febrile neutropenia was observed with 75 mg/m2 dose. | - |
dc.language | eng | - |
dc.publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/oraloncology | - |
dc.relation.ispartof | Oral Oncology | - |
dc.rights | NOTICE: this is the author’s version of a work that was accepted for publication in [Journal title]. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in PUBLICATION, [VOL#, ISSUE#, (DATE)] DOI# | - |
dc.subject | Chemotherapy | - |
dc.subject | Cisplatin | - |
dc.subject | Docetaxel | - |
dc.subject | Nasopharyngeal carcinoma | - |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols - adverse effects - therapeutic use | - |
dc.subject.mesh | Carcinoma - drug therapy - pathology - secondary | - |
dc.subject.mesh | Cisplatin - administration & dosage - adverse effects | - |
dc.subject.mesh | Nasopharyngeal Neoplasms - drug therapy - pathology | - |
dc.subject.mesh | Neutropenia - chemically induced | - |
dc.title | A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma | - |
dc.type | Article | - |
dc.identifier.email | Chua, DTT: dttchua@hkucc.hku.hk | - |
dc.identifier.email | Sham, JST: jstsham@hku.hk | - |
dc.identifier.authority | Chua, DTT=rp00415 | - |
dc.identifier.doi | 10.1016/j.oraloncology.2005.01.008 | - |
dc.identifier.pmid | 15975521 | - |
dc.identifier.scopus | eid_2-s2.0-20444490061 | - |
dc.identifier.hkuros | 124595 | - |
dc.identifier.volume | 41 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 589 | - |
dc.identifier.epage | 595 | - |
dc.identifier.isi | WOS:000230570600005 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1368-8375 | - |